🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

9 recruiting trials

for Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma NCT05879367Phase 18 sites📍 Birmingham📍 Detroit📍 New York Orbus Therapeutics, Inc. · Tests: Eflornithine (Dose Level 1), Eflornithine (Dose Level 2), Eflornithine (Dose Level -1), Temozolomide Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma NCT07416188Phase 1, Phase 21 site📍 Bethesda National Institute of Neurological Disorders and Stroke (NI… · Tests: LMP744, Conventional Surgery or Biopsy A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma NCT06552260EARLY Phase 13 sites📍 Boston📍 Boston📍 Boston Ugonma Chukwueke · Tests: Troriluzole Feasibility of ONCOhabitats for Surgical and Treatment Planning in IDH-Wildtype Glioblastoma (SINUE) NCT07111195n/a5 sites📍 Alicante📍 Barcelona📍 Murcia Juan M Garcia-Gomez · Tests: The ONCOhabitats software for MRI-based habitat segmentation TTFields Plus FET-PET-Guided Stereotactic Radiosurgery Versus TTFields Alone for Recurrent Glioblastoma (Tarrget 2.0) NCT07668869NA1 site📍 Bydgoszcz Prof. Franciszek Lukaszczyk Memorial Oncology Center · Tests: Tumor Treating Fields (TTFields), FET-PET-Guided Stereotactic Radiosurgery A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma NCT05765812Phase 1, Phase 216 sites📍 Chicago📍 New York📍 New York Debiopharm International SA · Tests: Debio 0123, Temozolomide, Radiotherapy A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients NCT07185880Phase 1, Phase 23 sites📍 Phoenix📍 Jacksonville📍 Rochester Myosin Therapeutics Inc. · Tests: MT-125 Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma NCT06430424n/a1 site📍 Bordeaux University Hospital, Bordeaux · Tests: Relapsed glioblastoma A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma NCT03970447Phase 2, Phase 363 sites📍 Birmingham📍 La Jolla📍 Los Angeles Global Coalition for Adaptive Research · Tests: Temozolomide, Lomustine, Regorafenib, Radiation, Paxalisib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy